Home>>Infectious Disease>> Viral Diseases>> RSV>>Sisunatovir

Sisunatovir Sale

(Synonyms: RV521) 目录号 : GC62216

Sisunatovir (RV521) 是一种口服 RSV 融合 (RSV-F) 蛋白抑制剂,对一组临床分离的 RSV-A 和 RSV-B 病毒具有很强的疗效,对 RSV-A 和 RSV-B 分离株的 IC50 分别为 1.4 nM 和 1.0 nM。

Sisunatovir Chemical Structure

Cas No.:1903763-82-5

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥1,113.00
现货
1mg
¥350.00
现货
5mg
¥1,050.00
现货
10mg
¥1,750.00
现货
25mg
¥3,150.00
现货
50mg
¥5,250.00
现货
100mg
¥8,050.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Sisunatovir (RV521), an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively[1].

[1]. DeVincenzo J, et al. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein. Antimicrob Agents Chemother. 2020;64(2):e01884-19. Published 2020 Jan 27.

Chemical Properties

Cas No. 1903763-82-5 SDF
别名 RV521
分子式 C23H22F4N4O 分子量 446.44
溶解度 DMSO : 3.33 mg/mL (7.46 mM; Need ultrasonic) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.2399 mL 11.1997 mL 22.3994 mL
5 mM 0.448 mL 2.2399 mL 4.4799 mL
10 mM 0.224 mL 1.12 mL 2.2399 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion

J Med Chem 2021 Apr 8;64(7):3658-3676.PMID:33729773DOI:10.1021/acs.jmedchem.0c01882

RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.